CASP1 and metabolic dysfunction-associated steatohepatitis: Although emricasan failed to yield positive outcomes for decompensation or mortality when tested in patients with decompensated MASH cirrhosis, a selective caspase-1 inhibitor effectively reduced inflammatory responses and fibrosis in a transgenic MASH model [119].